Crinetics Pharmaceuticals (CRNX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Key Insights
Critical company metrics and information
Share Price
$57.11Market Cap
$5.30 BillionTotal Outstanding Shares
92.74 Million SharesTotal Employees
210Dividend
No dividendIPO Date
July 18, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.crinetics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $-199.81 Million |
Net Cash Flow From Financing Activities | $494.32 Million |
Net Cash Flow From Investing Activities, Continuing | $-120.04 Million |
Net Cash Flow From Financing Activities, Continuing | $494.32 Million |
Net Cash Flow From Investing Activities | $-120.04 Million |
Net Cash Flow, Continuing | $174.47 Million |
Net Cash Flow From Operating Activities, Continuing | $-199.81 Million |
Net Cash Flow | $174.47 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Expenses | $307.81 Million |
Income/Loss From Continuing Operations After Tax | $-277.91 Million |
Income/Loss From Continuing Operations Before Tax | $-294.33 Million |
Diluted Average Shares | $158.85 Million |
Operating Income/Loss | $-306.77 Million |
Benefits Costs and Expenses | $218.54 Million |
Basic Average Shares | $158.85 Million |
Research and Development | $219.17 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Nonoperating Income/Loss | $33.53 Million |
Other Operating Expenses | $87.15 Million |
Net Income/Loss | $-277.91 Million |
Net Income/Loss Attributable To Parent | $-277.91 Million |
Basic Earnings Per Share | $3.70 |
Revenues | $1.04 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Depreciation and Amortization | $2.26 Million |
Costs And Expenses | $299.73 Million |
Diluted Earnings Per Share | $3.70 |
Net Income/Loss Available To Common Stockholders, Basic | $-277.91 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $877.59 Million |
Assets | $937.37 Million |
Other Non-current Assets | $48.08 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $832.98 Million |
Noncurrent Liabilities | $50.83 Million |
Current Liabilities | $53.56 Million |
Fixed Assets | $11.71 Million |
Cash | $862.70 Million |
Liabilities | $104.39 Million |
Other Current Assets | $14.89 Million |
Noncurrent Assets | $59.79 Million |
Equity | $832.98 Million |
Liabilities And Equity | $937.37 Million |
Other Current Liabilities | $48.62 Million |
Accounts Payable | $4.94 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.